Three Issues With Drugs in Running… and Why So Many Addicts Don’t Seek Treatment

Drugs and running are not a good combination. Why?

The following three issues will make the reasons clear.

1. Combining Drugs with Running Can Cause Physical Damage

Whenever someone uses drugs, he or she will experience both physical and psychological changes, some of which can happen immediately while others can occur over time. When people run or engage in other physical activities while they are on drugs, they can potentially experience negative side effects.

Often, drug use during physical activity can cause physical damage. Occasionally, the damage can be life-threatening.

For instance, one’s body could go into shock or completely shut down. And the more demanding the physical activity is, the higher the risk is of causing permanent damage.

2. Performance-Enhancing Drugs Can Be Dangerous

Some people who are serious about their fitness or compete professionally in marathons and other running competitions use performance-enhancing drugs to improve their physical abilities.

For instance, some runners and athletes use anabolic steroids to build muscle and increase their athletic performance.

Anabolic steroids and other performance-enhancing drugs are illegal in the US, and with good reason. They can cause various serious health issues, including high blood pressure, kidney damage, liver disease, and heart disease.

Running should primarily be about keeping fit and healthy, so it never makes sense for runners to use performance-enhancing drugs that can damage them physically.

3. Many Over-the-counter Drugs Can Cause Harm, Too

It is not only illegal drugs that can cause issues when running or engaging in other sports and physical activities. Runners should also avoid many over-the-counter prescription drugs.

For instance, the stimulant pseudoephedrine is an active ingredient that is found in decongestants like Sudafed. And pseudoephedrine can exacerbate underlying medical issues and enhance health risks for runners, especially when taken long-term.

The drug will shrink the blood vessels in your nose, which is good for reducing swelling and draining fluids in order to relieve congestion. But shrinking blood vessels in your nose also means your heart needs to work harder to pump blood through your body.

Therefore, runners and athletes who take pseudoephedrine are more at risk of things like heart problems. Other prescription drugs that runners should avoid include fluoroquinolones, non-steroidal anti-inflammatories, and corticosteroids.

You should always talk to your doctor about whether a medication you are prescribed could cause issues with running and other physical activities.

Why So Many Addicts Do Not Seek Treatment

Many runners continue to take drugs even when they know information like that outlined above because they become addicted to them. Sadly, many addicts do not seek treatment for their drug addiction problems.

One reason for that is that they find navigating addiction recovery barriers challenging. For instance, one common concern of people who struggle with substance abuse disorders is that it could negatively impact their employment.

Fearing being labeled as an addict is another common reason why addicts refuse to seek treatment. And sometimes it can simply be difficult for people to access the help they need due to things like not having a supportive network of friends and family or living in an isolated location.

The addiction itself can prevent people from getting help, too. That is because the brain changes when people take drugs regularly, and the brain becomes more interested in getting the next fix of drugs than it is in getting treatment.

Final Thoughts

If you are addicted to drugs, you should seek help. Not only will your running become a healthier activity. You will also feel psychologically and physically stronger over time.

On the other hand, if you continue to use drugs regularly, you could jeopardize your relationships, your work, and your health.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version